{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=REGN3500", "query": { "intervention": "REGN3500" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 15, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=REGN3500&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-04T07:57:08.464Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05326412", "title": "Mechanistic Study of the Effect of Itepekimab on Airway Inflammation in Patients With COPD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Obstructive Pulmonary Disease" ], "interventions": [ { "name": "Itepekimab SAR440340", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "40 Years to 70 Years" }, "enrollment_count": 49, "start_date": "2022-05-19", "completion_date": "2025-07-25", "has_results": true, "last_update_posted_date": "2026-08-31", "last_synced_at": "2026-09-04T07:57:08.464Z", "location_count": 7, "location_summary": "Torrance, California • Denver, Colorado • Miami, Florida + 4 more", "locations": [ { "city": "Torrance", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Miami", "state": "Florida" }, { "city": "Kansas City", "state": "Missouri" }, { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT05326412" }, { "nct_id": "NCT03387852", "title": "Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "SAR440340", "type": "DRUG" }, { "name": "Dupilumab", "type": "DRUG" }, { "name": "Fluticasone or Fluticasone/salmeterol combination", "type": "DRUG" }, { "name": "Placebo for SAR440340", "type": "DRUG" }, { "name": "Placebo for dupilumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 296, "start_date": "2018-03-12", "completion_date": "2019-08-07", "has_results": true, "last_update_posted_date": "2022-06-14", "last_synced_at": "2026-09-04T07:57:08.464Z", "location_count": 18, "location_summary": "Birmingham, Alabama • Long Beach, California • Los Angeles, California + 14 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Rolling Hills Estates", "state": "California" }, { "city": "San Jose", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03387852" }, { "nct_id": "NCT06280391", "title": "A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bronchiectasis" ], "interventions": [ { "name": "Itepekimab (SAR440340)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 312, "start_date": "2024-02-20", "completion_date": "2026-02-02", "has_results": false, "last_update_posted_date": "2026-02-12", "last_synced_at": "2026-09-04T07:57:08.464Z", "location_count": 32, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 26 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Westminster", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06280391" }, { "nct_id": "NCT06834360", "title": "A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Rhinosinusitis With Nasal Polyps" ], "interventions": [ { "name": "Itepekimab (SAR440340)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Mometasone furoate nasal spray (MFNS)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 216, "start_date": "2025-02-06", "completion_date": "2027-10-11", "has_results": false, "last_update_posted_date": "2026-06-02", "last_synced_at": "2026-09-04T07:57:08.464Z", "location_count": 15, "location_summary": "Birmingham, Alabama • La Mesa, California • Los Angeles, California + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Mesa", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Napa", "state": "California" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06834360" }, { "nct_id": "NCT03736967", "title": "Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "REGN3500", "type": "DRUG" }, { "name": "Dupilumab", "type": "DRUG" }, { "name": "REGN3500 + Dupilumab Combo", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 206, "start_date": "2018-11-12", "completion_date": "2020-07-28", "has_results": true, "last_update_posted_date": "2021-11-01", "last_synced_at": "2026-09-04T07:57:08.464Z", "location_count": 22, "location_summary": "Phoenix, Arizona • Fountain Valley, California • Long Beach, California + 17 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03736967" }, { "nct_id": "NCT04701983", "title": "Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Obstructive Pulmonary Disease" ], "interventions": [ { "name": "Itepekimab SAR440340", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "40 Years to 85 Years" }, "enrollment_count": 1127, "start_date": "2020-12-16", "completion_date": "2025-08-27", "has_results": false, "last_update_posted_date": "2026-04-15", "last_synced_at": "2026-09-04T07:57:08.464Z", "location_count": 86, "location_summary": "Birmingham, Alabama • Jasper, Alabama • Chandler, Arizona + 65 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Jasper", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT04701983" }, { "nct_id": "NCT03546907", "title": "Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of SAR440340 (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Obstructive Pulmonary Disease" ], "interventions": [ { "name": "SAR440340", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Any Inhaled Corticosteroids as prescribed by treating physician as standard of care", "type": "DRUG" }, { "name": "Any Long Acting Beta Agonist as prescribed by treating physician as standard of care", "type": "DRUG" }, { "name": "Any Long Acting Muscarinic Agonist as prescribed by treating physician as standard of care", "type": "DRUG" }, { "name": "Any short-acting β agonist as prescribed by treating physician as standard of care", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "40 Years to 75 Years" }, "enrollment_count": 343, "start_date": "2018-07-16", "completion_date": "2020-02-21", "has_results": true, "last_update_posted_date": "2022-11-22", "last_synced_at": "2026-09-04T07:57:08.464Z", "location_count": 16, "location_summary": "Los Angeles, California • Riverside, California • Rolling Hills Estates, California + 13 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Riverside", "state": "California" }, { "city": "Rolling Hills Estates", "state": "California" }, { "city": "Westminster", "state": "California" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03546907" }, { "nct_id": "NCT03112577", "title": "Study of REGN3500 and Dupilumab in Patients With Asthma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Asthma, Allergic" ], "interventions": [ { "name": "REGN3500", "type": "DRUG" }, { "name": "Dupilumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Fluticasone propionate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 32, "start_date": "2017-06-15", "completion_date": "2019-12-09", "has_results": false, "last_update_posted_date": "2020-01-18", "last_synced_at": "2026-09-04T07:57:08.464Z", "location_count": 1, "location_summary": "Cypress, California", "locations": [ { "city": "Cypress", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03112577" }, { "nct_id": "NCT06691113", "title": "A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti--IL-33 mAb) in Participants With Chronic Rhinosinusitis Without Nasal Polyps", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Rhinosinusitis Without Nasal Polyps" ], "interventions": [ { "name": "Itepekimab (SAR440340)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Mometasone furoate nasal spray (MFNS)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 66, "start_date": "2024-12-16", "completion_date": "2026-08-12", "has_results": false, "last_update_posted_date": "2026-08-25", "last_synced_at": "2026-09-04T07:57:08.464Z", "location_count": 10, "location_summary": "Birmingham, Alabama • La Jolla, California • Murrieta, California + 7 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Murrieta", "state": "California" }, { "city": "Roseville", "state": "California" }, { "city": "Wheat Ridge", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT06691113" }, { "nct_id": "NCT03738423", "title": "Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "REGN3500", "type": "DRUG" }, { "name": "REGN3500-Matching Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 129, "start_date": "2018-11-13", "completion_date": "2020-07-24", "has_results": true, "last_update_posted_date": "2022-06-10", "last_synced_at": "2026-09-04T07:57:08.464Z", "location_count": 31, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 24 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03738423" } ] }